(Q40746072)

23 September 2017

1 reference

title

Treatment and prevention options for respiratory syncytial virus infections (English)

1 reference

23 September 2017

Levin MJ

1

1 reference

23 September 2017

language of work or name

English

0 references

publication date

1 May 1994

1 reference

The Journal of Pediatrics

23 September 2017

published in

1 reference

23 September 2017

volume

124

1 reference

23 September 2017

issue

5 Pt 2

1 reference

23 September 2017

page(s)

S22-7

1 reference

Serologic evidence of respiratory syncytial virus infection in nursing home patients

23 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2894%2970187-3

Aerosolized ribavirin treatment of infants with respiratory syncytial viral infection. A randomized double-blind study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2894%2970187-3

In re ribavirin: a case of premature adjudication?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2894%2970187-3

A controlled trial of aerosolized ribavirin in infants receiving mechanical ventilation for severe respiratory syncytial virus infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2894%2970187-3

Expression of the F glycoprotein of respiratory syncytial virus by a recombinant vaccinia virus: comparison of the individual contributions of the F and G glycoproteins to host immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2894%2970187-3

Human monoclonal Fab fragments derived from a combinatorial library bind to respiratory syncytial virus F glycoprotein and neutralize infectivity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2894%2970187-3

The fusion glycoproteins of human respiratory syncytial virus of subgroups A and B: sequence conservation provides a structural basis for antigenic relatedness

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2894%2970187-3

Immunoprophylaxis and immunotherapy of respiratory syncytial virus infection in the cotton rat.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2894%2970187-3

Intravenous immunoglobulin treatment of respiratory syncytial virus infections in infants and young children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2894%2970187-3

Topically administered immunoglobulin reduces pulmonary respiratory syncytial virus shedding in owl monkeys

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2894%2970187-3

Immunotherapy of respiratory syncytial virus infection in cotton rats (Sigmodon fulviventer) using IgG in a small-particle aerosol

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2894%2970187-3

Immunoglobulin administration and ribavirin therapy: efficacy in respiratory syncytial virus infection of the cotton rat.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2894%2970187-3

Monoclonal antibodies protect against respiratory syncytial virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2894%2970187-3

Pathological changes in virus infections of the lower respiratory tract in children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2894%2970187-3

Early ribavirin treatment of respiratory syncytial viral infection in high-risk children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2894%2970187-3

Prophylactic administration of respiratory syncytial virus immune globulin to high-risk infants and young children. The Respiratory Syncytial Virus Immune Globulin Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2894%2970187-3

Risk of respiratory syncytial virus infection for infants from low-income families in relationship to age, sex, ethnic group, and maternal antibody level

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2894%2970187-3

Respiratory syncytial virus in early infancy. Circulating antibody and the severity of infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2894%2970187-3

Antibodies to respiratory syncytial virus polypeptides and their significance in human infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2894%2970187-3

Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2894%2970187-3

Respiratory virus immunization. I. A field trial of two inactivated respiratory virus vaccines; an aqueous trivalent parainfluenza virus vaccine and an alum-precipitated respiratory syncytial virus vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2894%2970187-3

Enhanced pulmonary histopathology is observed in cotton rats immunized with formalin-inactivated respiratory syncytial virus (RSV) or purified F glycoprotein and challenged with RSV 3-6 months after immunization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2894%2970187-3

Immunogenicity and safety of respiratory syncytial virus subunit vaccine in seropositive children 18-36 months old.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2894%2970187-3

Immunogenicity of purified F glycoprotein of respiratory syncytial virus: clinical and immune responses to subsequent natural infection in children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2894%2970187-3

Cotton rats previously immunized with a chimeric RSV FG glycoprotein develop enhanced pulmonary pathology when infected with RSV, a phenomenon not encountered following immunization with vaccinia--RSV recombinants or RSV.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2894%2970187-3

Parenteral administration of live respiratory syncytial virus vaccine: results of a field trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2894%2970187-3

Molecular mechanisms of action of ribavirin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2894%2970187-3

7 January 2021

Effectiveness of topically administered neutralizing antibodies in experimental immunotherapy of respiratory syncytial virus infection in cotton rats.

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2894%2970187-3

7 January 2021

Protection from respiratory syncytial virus infection in cotton rats by passive transfer of monoclonal antibodies

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2894%2970187-3

7 January 2021

Mechanism of antibody-mediated viral clearance in immunotherapy of respiratory syncytial virus infection of cotton rats

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2894%2970187-3

7 January 2021

Administration of a highly attenuated, live respiratory syncytial virus vaccine to adults and children.

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2894%2970187-3

7 January 2021

10.1016/S0022-3476(94)70187-3

Identifiers

DOI

1 reference

23 September 2017

1 reference